Conformationally constrained butyrophenones as new pharmacological tools to study 5-HT2A and 5-HT2C receptor behaviours

被引:8
作者
Brea, J
Masaguer, CF
Villazón, M
Cadavid, MI
Raviña, E
Fontaine, F
Dezi, C
Pastor, M
Sanz, F
Loza, MI [1 ]
机构
[1] Univ Santiago de Compostela, Dept Farmacol, Fac Farm, Santiago De Compostela 15782, Spain
[2] Univ Santiago de Compostela, Dept Quim Organ, Quim Farmaceut Lab, Fac Farm, Santiago De Compostela 15782, Spain
[3] Univ Pompeu Fabra, Res Grp Biomed Informat GRIB, Barcelona 08003, Spain
关键词
3D-QSAR models; 5-HT2A; 5-HT2C; butyrophenone; GRIND; inverse agonism; receptor conformations;
D O I
10.1016/S0223-5234(03)00054-0
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study presents new pharmacological and molecular modelling studies on a recently described series of conformationally constrained butyrophenones. Alignment-free three-dimensional quantitative structure-activity relationship models developed on the basis of GRid Independent descriptors and partial least squares regression analysis, allow feasible predictions of activity of new compounds and reveal structural requirements for optimal affinity, particularly in the case of the 5-HT2A receptor. The requirements for the 5-HT(2A)affinity consist in a precise distance between hydrogen bond donor (protonated amino group) and hydrogen bond acceptor groups, as well as an optimal distance between the protonated amino group and the farthest extreme of the compounds. Another significant result has been the characterisation of two structurally similar compounds as interesting pharmacological tools (1-[(4-Oxo-4,5,6,7-tetrahydrobenzo[b]furan-5-yl)ethyl]-4-(6-fluorobenzisoxazol-3-yl)piperidine and 1-[(4-Oxo-4,5,6,7-teti-aliydrobenzo[b]furan-6-yl)methyl]-4-(6-fluorobenzisoxazol-3-yl)piperidine). In spite of their structural similarity, the first compound shows clearly higher affinity for the 5-HT2C receptor (about 100 fold) and higher Meltzer ratio (1.17 vs. 0.99) than the second. Moreover, the first compound inhibits arachidonic acid release in a biphasic, concentration-dependent way in functional experiments at the 5-HT2C receptor and it acts as inverse agonist at the 5-HT2C receptor, behaviours that are not shown by the second compound. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.
引用
收藏
页码:433 / 440
页数:8
相关论文
共 38 条
  • [1] Serotonin model of schizophrenia: emerging role of glutamate mechanisms
    Aghajanian, GK
    Marek, GJ
    [J]. BRAIN RESEARCH REVIEWS, 2000, 31 (2-3) : 302 - 312
  • [2] GENERATING OPTIMAL LINEAR PLS ESTIMATIONS (GOLPE) - AN ADVANCED CHEMOMETRIC TOOL FOR HANDLING 3D-QSAR PROBLEMS
    BARONI, M
    COSTANTINO, G
    CRUCIANI, G
    RIGANELLI, D
    VALIGI, R
    CLEMENTI, S
    [J]. QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 1993, 12 (01): : 9 - 20
  • [3] Berg KA, 1999, MOL PHARMACOL, V55, P863
  • [4] Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus
    Berg, KA
    Maayani, S
    Goldfarb, J
    Scaramellini, C
    Leff, P
    Clarke, WP
    [J]. MOLECULAR PHARMACOLOGY, 1998, 54 (01) : 94 - 104
  • [5] New serotonin 5-HT2A, 5-HT2B, and 5-HT2c receptor antagonists:: Synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones
    Brea, J
    Rodrigo, J
    Carrieri, A
    Sanz, F
    Cadavid, MI
    Enguix, MJ
    Villazón, M
    Mengod, G
    Caro, Y
    Masaguer, CF
    Raviña, E
    Centeno, NB
    Carotti, A
    Loza, MI
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (01) : 54 - 71
  • [6] Cussac D, 2000, N-S ARCH PHARMACOL, V361, P549
  • [7] Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery
    de Ligt, RAF
    Kourounakis, AP
    Ijzerman, AP
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (01) : 1 - 12
  • [8] Ereshefsky L, 1996, PSYCHOPHARMACOL BULL, V32, P101
  • [9] Gasteiger J., 1990, Tetrahedron ComputerMethodology, V3, P537, DOI DOI 10.1016/0898-5529(90)90156-3
  • [10] Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice
    Gleason, SD
    Shannon, HE
    [J]. PSYCHOPHARMACOLOGY, 1997, 129 (01) : 79 - 84